ACTU
CGTX
LTRN
AZTR
INAB

Leslie W. Kreis

Known title: DirectorCIK: 0001813316

Leslie W. Kreis's purchase track record

How the stock did after each of Leslie W. Kreis's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.

Purchases measured
9
of 9 since August 16, 2022
Stock higher 6 months later
33%
3 months: 33%
Median 6-month return
-12.7%
3 months: -15.3%
Beat the S&P 500
22%
median -23.4% vs. index
PurchaseStockAmount3 months6 months
6/27/2025ACTU$500K+15.6%+8.5%
8/14/2024ACTU$4.00M-6.5%-12.7%
6/21/2023AZTR$3.00M-63.7%-73.5%
12/12/2022INAB$186K-50.2%-4.0%
11/28/2022CGTX$43K-36.9%-19.6%
11/15/2022CGTX$1.90M+25.5%+15.9%
9/28/2022INAB$51K+3.8%-34.8%
8/26/2022INAB$103K-17.3%-25.5%
8/16/2022INAB$3.47M-15.3%+1.9%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 1, 2026

ACTU Included in Recent Healthcare Stock Movers. ACTU was listed among 12 healthcare shares that moved in Monday's after‑market session, Friday's intraday session, and Friday's pre‑market session, according to Benzinga reports. The stock is trading near its 10‑touch support level of $1.93 and has a moderate RSI of 39.1, indicating it is not yet overbought or oversold. These sessions show recent interest in the company, but no specific catalyst was highlighted.

this person other insiders at ACTU

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 29, 2026

Cognition Therapeutics Sets FDA Type C Meeting for Oct. 20. Cognition Therapeutics announced it will hold a Type C meeting with the FDA on October 20 regarding the planned trial of zervimesine. This regulatory step is a key milestone for the drug's development path. The company's stock currently trades within a wide 52-week range, reflecting the uncertainty typical of clinical-stage biotech firms.

this person other insiders at CGTX

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 30, 2026

Lantern Pharma Announces $8M Direct Offering and AI Roadmap. Lantern Pharma said it will raise up to $8 million through a registered direct offering. The company also outlined its Open‑Medicine AI platform roadmap, highlighting plans to use agentic AI for drug development. It presented these ideas on Bloomberg Television and in a SeekingAlpha slideshow. The move could support future product pipelines, while the stock’s low RSI and recent volume spike suggest increased investor interest.

this person other insiders at LTRN

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 3, 2026

Azitra Announces $3.5M Common Stock Sale Agreement and Updated Valuation. Azitra Inc. entered a sales agreement with A.G.P. to offer up to $3.5 million of common stock. The company also updated its valuation to reflect progress in its cosmetic and EGFRi rash programs. These developments were noted in a Benzinga report that listed Azitra among 12 healthcare stocks moving in Thursday’s after‑market session.

this person other insiders at AZTR

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 7, 2026

IN8bio Reports Inducement Grant Under Nasdaq Rule. IN8bio disclosed an inducement grant in compliance with Nasdaq Listing Rule 5635(c)(4). This filing is a standard corporate governance procedure used to attract or retain key employees. The stock is currently trading near its 52-week high, with technical indicators showing recent support rejection.

this person other insiders at INAB

Transaction History

ACTU▲ Buy$500K
CGTX▲ Buy$0
LTRN▼ Sell$22K
LTRN▼ Sell$38K
LTRN▼ Sell$6K
LTRN▼ Sell$44K
LTRN▼ Sell$13K
LTRN▼ Sell$37K
LTRN▼ Sell$10K
LTRN▼ Sell$73K
LTRN▼ Sell$22K
LTRN▼ Sell$63K
LTRN▼ Sell$581
LTRN▼ Sell$996
LTRN▼ Sell$153
LTRN▼ Sell$350
LTRN▼ Sell$1K
LTRN▼ Sell$10
LTRN▼ Sell$17
LTRN▼ Sell$7
LTRN▼ Sell$3
LTRN▼ Sell$17
LTRN▼ Sell$11K
LTRN▼ Sell$3K
LTRN▼ Sell$22K
LTRN▼ Sell$7K
LTRN▼ Sell$19K
LTRN▼ Sell$8K
LTRN▼ Sell$2K
LTRN▼ Sell$15K
LTRN▼ Sell$5K
LTRN▼ Sell$13K
LTRN▼ Sell$12K
LTRN▼ Sell$20K
LTRN▼ Sell$3K
LTRN▼ Sell$23K
LTRN▼ Sell$7K
ACTU▲ Buy$3.0M
ACTU▲ Buy$1.0M
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell—
ACTU▼ Sell$43K
ACTU▼ Sell$48K
ACTU▼ Sell$139K
ACTU▼ Sell$156K
ACTU▼ Sell$19K
ACTU▼ Sell$21K
CGTX▲ Buy$0
LTRN▼ Sell$12K
LTRN▼ Sell$88K
LTRN▼ Sell$27K
LTRN▼ Sell$6K
LTRN▼ Sell$43K
LTRN▼ Sell$13K
LTRN▼ Sell$9K
LTRN▼ Sell$67K
LTRN▼ Sell$20K
LTRN▼ Sell$34K
LTRN▼ Sell$250K
LTRN▼ Sell$77K
LTRN▼ Sell$20K
LTRN▼ Sell$153K
LTRN▼ Sell$47K
LTRN▼ Sell$23K
LTRN▼ Sell$23K
LTRN▼ Sell$172K
LTRN▼ Sell$172K
LTRN▼ Sell$53K
LTRN▼ Sell$53K
LTRN▼ Sell$185K
LTRN▼ Sell$315K
CGTX▲ Buy$525K
AZTR▼ Sell—
AZTR▲ Buy$349K
AZTR▼ Sell—
AZTR▼ Sell—
AZTR▲ Buy—
AZTR▲ Buy$2.3M
AZTR▼ Sell—
AZTR▼ Sell—
AZTR▲ Buy—
AZTR▲ Buy$369K
AZTR▼ Sell—
AZTR▼ Sell—
AZTR▼ Sell—
AZTR▼ Sell—
AZTR▼ Sell—
AZTR▼ Sell—
AZTR▼ Sell—
AZTR▼ Sell—
AZTR▼ Sell—
AZTR▼ Sell—
AZTR▲ Buy—
CGTX▲ Buy$0
INAB▲ Buy$23K
INAB▲ Buy$141K
INAB▲ Buy$22K
CGTX▲ Buy$5K
CGTX▲ Buy$32K
CGTX▲ Buy$5K
CGTX▲ Buy$12K
CGTX▲ Buy$76K
CGTX▲ Buy$12K
CGTX▲ Buy$221K
CGTX▲ Buy$1.4M
CGTX▲ Buy$210K
LTRN▼ Sell$258K
LTRN▼ Sell$442K
LTRN▼ Sell$78K
LTRN▼ Sell$583K
LTRN▼ Sell$179K
INAB▲ Buy$6K
INAB▲ Buy$38K
INAB▲ Buy$6K
LTRN▼ Sell$27K
LTRN▼ Sell$7K
LTRN▼ Sell$27K
LTRN▼ Sell$7K
INAB▲ Buy$10K
INAB▲ Buy$61K
INAB▲ Buy$9K
INAB▲ Buy$3K
INAB▲ Buy$17K
INAB▲ Buy$3K
INAB▲ Buy$12K
INAB▲ Buy$73K
INAB▲ Buy$11K
INAB▲ Buy$2.6M
INAB▲ Buy$414K
INAB▲ Buy$392K
LTRN▼ Sell$11430.8M
LTRN▼ Sell$3910.7M

We use analytics to understand how market-wall is used. No personal data is sold.